LATITUDE Pharmaceuticals Receives USPTO Notice of Allowance for Novel Injectable Depot Formulation Platform

MENAFN Press - 21/09/2016 (MENAFN Press)

SAN DIEGO, CA, U.S.A., September 20, 2016 / LATITUDE Pharmaceuticals, Inc. (LATITUDE), announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for a U.S. patent application covering LATITUDE's PG (Phospholipid Gel) Depot, a phospholipid gel composition that enables sustained localized or systemic drug delivery for small molecules, peptides or proteins with up to one-week release from a single intramuscular or subcutaneous injection. LATITUDE's PG Depot properties are particularly well-suited for prolonged delivery of drugs that require a high dose and/or frequent injections as well as drugs with poor stability or solubility. Individual PG Depot formulations can be custom-tailored to create optimized drug-release kinetics, including peak-less profiles. The PG Depot is composed entirely of FDA-approved injectable ingredients, and its simple production process is significantly less expensive than other injectable depot technologies such as PLGA microspheres and liposomes. LATITUDE's PG Depot has proven to be safe for both human as well as veterinary applications, with human product candidates already in Phase II clinical studies.

Comments: This technology competes with the technology used by Pacira